| Risk Dimension | Evidence Quality | Severity if Realized | Practical Impact | |---|---|---|---| | Absorption interference (oral, same-time dosing) | Indirect/mechanistic | Moderate (reduced efficacy) | High: fixable with timing | | Direct chelation (glutathione binds alendronate) | None documented | Low | Low | | Pharmacodynamic antagonism (bone) | None documented | Potentially none or positive | Low | | Hepatic CYP interaction | Not applicable | None | None | | Renal clearance competition (IV glutathione) | Theoretical only | Unknown | Moderate precaution warranted | The dominant clinical concern is absorption interference, and it is entirely preventable with correct timing
Standard oral glutathione has a well-documented absorption problem, with research dating back decades showing much of it breaks down before reaching the bloodstream
B cha khong 27.7mg Glutathione t nhin trong mi 100g
The blinding of subjects and researchers was reported in four studies (Reference Hashim, Anwar and El-Fatah22,Reference Nasr9,Reference Chandil, Pande and Sen27,Reference Gayatri, Kumar and Kumar28)
These characteristics are representative of the T2D population seen in diabetes specialist care in Italy